CN112437664A - 用于治疗胰腺癌的化合物 - Google Patents

用于治疗胰腺癌的化合物 Download PDF

Info

Publication number
CN112437664A
CN112437664A CN201980046672.7A CN201980046672A CN112437664A CN 112437664 A CN112437664 A CN 112437664A CN 201980046672 A CN201980046672 A CN 201980046672A CN 112437664 A CN112437664 A CN 112437664A
Authority
CN
China
Prior art keywords
compound
another embodiment
alkyl
formula
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980046672.7A
Other languages
English (en)
Chinese (zh)
Inventor
李伟
D·D·米勒
S·乔汉
V·K·卡什亚普
W·清辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of CN112437664A publication Critical patent/CN112437664A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN201980046672.7A 2018-05-15 2019-05-15 用于治疗胰腺癌的化合物 Pending CN112437664A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671833P 2018-05-15 2018-05-15
US62/671,833 2018-05-15
PCT/US2019/032476 WO2019222392A1 (en) 2018-05-15 2019-05-15 Compounds for treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
CN112437664A true CN112437664A (zh) 2021-03-02

Family

ID=68541005

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980046672.7A Pending CN112437664A (zh) 2018-05-15 2019-05-15 用于治疗胰腺癌的化合物

Country Status (9)

Country Link
US (1) US20190374512A1 (https=)
EP (1) EP3793548A4 (https=)
JP (1) JP2021523915A (https=)
KR (1) KR20210021982A (https=)
CN (1) CN112437664A (https=)
AU (1) AU2019270091A1 (https=)
CA (1) CA3099922A1 (https=)
MX (1) MX2020012292A (https=)
WO (1) WO2019222392A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230413A1 (es) * 2020-04-03 2023-03-07 Veru Inc Metodos de tratamiento del coronavirus
CA3215936A1 (en) * 2021-04-05 2022-10-13 Veru Inc. Methods of treating inflammation
CN119212696A (zh) * 2022-04-28 2024-12-27 维鲁公司 [2-(1h-吲哚-3-基)-1h-咪唑-4-基](3,4,5-三甲氧基)甲酮和其盐的多晶型物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071524A1 (en) * 2010-03-01 2012-03-22 Yan Lu Compounds for treatment of cancer
CN102883607A (zh) * 2010-03-01 2013-01-16 Gtx公司 用于治疗癌的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
MX2010014066A (es) * 2008-06-16 2011-06-01 Univ Tennessee Res Foundation Compuestos para el tratamiento del cancer.
JP5997156B2 (ja) * 2010-08-24 2016-09-28 ジーティーエックス・インコーポレイテッド 癌の治療のための化合物
CN105163584B (zh) * 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071524A1 (en) * 2010-03-01 2012-03-22 Yan Lu Compounds for treatment of cancer
CN102883607A (zh) * 2010-03-01 2013-01-16 Gtx公司 用于治疗癌的化合物

Also Published As

Publication number Publication date
EP3793548A4 (en) 2022-03-09
AU2019270091A1 (en) 2020-12-24
WO2019222392A1 (en) 2019-11-21
EP3793548A1 (en) 2021-03-24
KR20210021982A (ko) 2021-03-02
JP2021523915A (ja) 2021-09-09
CA3099922A1 (en) 2019-11-21
US20190374512A1 (en) 2019-12-12
MX2020012292A (es) 2021-03-29

Similar Documents

Publication Publication Date Title
JP7342183B2 (ja) 表皮水疱症及び関連する結合組織疾患の治療におけるカンナビノイドの局所製剤の使用
JP7114745B2 (ja) トリプルネガティブ乳癌および卵巣癌の治療のための化合物
KR102246652B1 (ko) 암 치료용 화합물
JP5879273B2 (ja) 癌を処置するための化合物
KR101495950B1 (ko) 혈관 누수 증후군 치료 방법
RU2762111C1 (ru) Соединения для лечения рака
JP2010168387A (ja) マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体
KR102452370B1 (ko) 신경교종을 포함하는 암을 치료하기 위해 에플로르니틴 및 이의 유도체 및 동족체를 사용하기 위한 조성물 및 방법
AU2022200774A1 (en) Compounds, compositions and methods for prevention and/or treatment of cancer
CN112437664A (zh) 用于治疗胰腺癌的化合物
JP2020530477A (ja) Ｎｒ４ａ１リガンド、医薬組成物、及び関連する使用方法
JP7237383B2 (ja) アンドロゲン依存性又は非依存性前立腺癌細胞の抑制用の組成物及びそれを含有する前立腺癌の医薬製剤
CA2868120C (en) Kinase inhibitors for the treatment of cancer
KR20180120765A (ko) 증식성 질환을 위한 조합 치료
HK40043322A (en) Compounds for treatment of pancreatic cancer
CN106132437A (zh) 作为脑癌治疗用治疗剂的mao抑制剂及其缀合物
HK40043706A (en) Compounds for treatment of triple negative breast cancer and ovarian cancer
RU2776897C2 (ru) Соединения для лечения трижды негативного рака молочной железы и рака яичника
CN112996521A (zh) 用于诊断、治疗和预防赘生性和神经性障碍的组合物和方法
US20100022600A1 (en) Methods and compositions for treating central nervous system tumors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40043322

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210302